AB Science Shares Insights on Masitinib for Multiple Sclerosis
Recently, AB Science SA (Euronext - FR0010557264 - AB) provided important updates on masitinib, an experimental treatment aimed at progressive forms of multiple sclerosis (MS). This announcement follows extensive discussions and findings shared at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference.
What is Masitinib and Its Development Timeline?
Masitinib is currently undergoing evaluation in the MAXIMS study (AB20009), a randomized, double-blind, phase 3 clinical trial that examines how effective it is for patients with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive multiple sclerosis (nSPMS). Participants in this study have Expanded Disability Status Scale (EDSS) scores ranging from 3.0 to 6.0, have shown disease progression over the past two years, and do not display T1 Gadolinium-enhancing brain lesions.
Key Findings from the Study
The primary goal of the MAXIMS study is to see how well masitinib can slow down disability progression in MS patients. Recent updates from ECTRIMS 2024 have strengthened the scientific premise that targeting microglia in nSPMS offers a promising therapeutic direction. This research also highlighted the drug tolebrutinib, which works by targeting Bruton's Tyrosine Kinase (BTK).
Masitinib takes a different approach by acting on microglia via the M-CSFR1 pathway (Macrophage Colony Stimulating Factor Receptor-1). Earlier phase 2B trials (AB07002) showed promising results, which aligned closely with findings from studies involving tolebrutinib.
Comparative Efficacy of Masitinib and Tolebrutinib
An in-depth comparison of effectiveness revealed some important data:
- At the three-month mark, masitinib demonstrated a 37% reduction in EDSS progression compared to a 23% reduction with tolebrutinib, even though the trial conditions varied.
- At six months, masitinib showed a 32% decrease in EDSS progression, closely approximating tolebrutinib's 31% reduction.
Masitinib’s Unique Advantages
Masitinib’s benefits extend beyond just slowing disease progression. The study showcased notable improvements in manual dexterity, assessed through the 9-hole Peg test, with masitinib outperforming expectations. There’s also potential for it to lower serum neurofilament light chain (NfL) concentrations in MS animal models, a sign that it may help reduce neuronal damage.
In addition to its effects on microglia, masitinib interacts with mast cells, which play a vital role in the pathology of progressive MS. This multi-target strategy is backed by considerable research highlighting the significance of mast cells in neuroinflammation and related central nervous system disorders.
Masitinib's Strong Safety Profile
Masitinib boasts a robust safety record from its trials, with data accumulated from over 2,200 patients who have received at least one dose for various conditions. Notably, more than 1,300 patients have been treated for over six months, and nearly 1,000 have continued for more than a year, allowing for a thorough evaluation of its safety. On the other hand, BTK inhibitors present potential safety issues, such as an increased risk of liver injuries and infections, suggesting masitinib might be a safer treatment alternative.
Looking Ahead: Masitinib’s Future Potential
In summary, masitinib shows great promise as a viable alternative when compared to existing BTK inhibitors for addressing unmet medical needs in both primary and non-active secondary progressive forms of MS. Professor Patrick Vermersch, MD, the principal investigator of the MAXIMS study, emphasized the significance of these findings, noting that masitinib, alongside BTK inhibitors, holds considerable potential in tackling these complex forms of MS.
Frequently Asked Questions
What is masitinib?
Masitinib is a protein kinase inhibitor being investigated for various conditions, including progressive multiple sclerosis.
How does masitinib work in treating multiple sclerosis?
Masitinib targets microglia via the M-CSFR1 pathway, aiming to slow disease progression and enhance neurological function.
What were the key findings of the MAXIMS study?
The MAXIMS study showed that masitinib significantly reduced EDSS progression compared to a placebo, highlighting its effectiveness in progressive MS treatment.
What is the safety profile of masitinib?
Masitinib has a robust safety record with extensive long-term exposure showing no increased risks typically associated with BTK inhibitors.
How does masitinib compare to other treatments for MS?
Masitinib offers a unique approach by targeting both microglia and mast cells, potentially positioning it as a safer and more effective alternative to existing therapies.
